|
|
|
prIME Oncology invites you to view exciting news released from the 2010 Oncology Annual Meeting
in Chicago.
|
|
|
 |
|
7 JUNE 2010
|
| |
|
These Clinical Spotlight interviews, with accompanying eNewsflash and downloadable slides, discuss the topic of targeting angiogenesis in the treatment of ovarian cancer with a focus on the following data release:
#LBA1: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study
The first interview is an expert analysis with Gini Fleming, MD, from the University of Chicago, Illinois in the United States, and Bradley Monk, MD, from the University of California Irvine, Orange, California, United States
The second interview is a supplemental perspective and discussion with Bradley Monk, MD, from the University of California Irvine, Orange, California, United States, and Michael Birrer, MD, PhD, from the Massachusetts General Hospital, Boston, Massachusetts in the United States.
View the Primary Expert Analysis with Gini Fleming, MD, and Bradley Monk, MD, and access downloadable slides 
View the Supplemental Perspectives and Discussion with Bradley Monk, MD, and Michael Birrer, MD, PhD, and access downloadable slides
View eNewsflash
|
| |
|
|
| |
|
|
|
|
|
|
|
|
